Genpharmasec

Which are the latest news on Genpharmasec?

Why is Genpharmasec Ltd falling/rising?

As of 10-Aug, Genpharmasec Ltd's stock price is 1.05, down 0.94%, with significant declines of 19.85% year-to-date and 47.24% over the past year. The stock is underperforming its sector, showing bearish trends in moving averages and declining investor participation.

As of 10-Aug, Genpharmasec Ltd's stock price is currently at 1.05, reflecting a decrease of 0.01 or 0.94%. The stock has shown a significant decline over various periods, with a year-to-date drop of 19.85% and a staggering 47.24% decrease over the past year. In the last three years, the stock has fallen by 46.43%, while the benchmark Sensex has risen by 19.57% during the same period.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.96%. Additionally, the stock's moving averages show that it is higher than the 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the longer term. Furthermore, there has been a notable decline in investor participation, with delivery volume on August 6 falling by 27.57% compared to the 5-day average. This decline in trading activity indicates a lack of interest from investors, contributing to the stock's downward movement.<BR><BR>Overall, the combination of poor performance relative to the benchmark, declining investor participation, and unfavorable moving averages are key factors contributing to the falling stock price of Genpharmasec Ltd.

When is the next results date for Genpharmasec Ltd?

The next results date for Genpharmasec Ltd is 11 August 2026.

The next results date for Genpharmasec Ltd is scheduled for 11 August 2026.

How big is Genpharmasec?

As of 10th June, Genpharmasec Ltd has a market capitalization of 62.00 Cr and reported net sales of 139.94 Cr and a net profit of 0.44 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Genpharmasec Ltd has a market capitalization of 62.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 139.94 Cr, while the sum of Net Profit for the same period is 0.44 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025, with Shareholder's Funds amounting to 65.16 Cr and Total Assets valued at 79.43 Cr.

Who are in the management team of Genpharmasec?

The management team of Genpharmasec includes Ulhas Narayan Deosthale (Executive Director), Rajesh Sadhwani and Sneha Sadhwani (Non-Executive Directors), Siddhesh Shankar Shende, Mayur Bharatbhai Bhatt, and Sachin Aphandkar (Independent Directors), along with Heta Shah (Company Secretary & Compliance Officer).

The management team of Genpharmasec includes the following individuals:<BR><BR>1. **Ulhas Narayan Deosthale** - Executive Director / Whole Time Director<BR>2. **Rajesh Sadhwani** - Non-Executive & Non-Independent Director<BR>3. **Sneha Sadhwani** - Non-Executive & Non-Independent Director<BR>4. **Siddhesh Shankar Shende** - Independent Non-Executive Director<BR>5. **Mayur Bharatbhai Bhatt** - Independent Director<BR>6. **Sachin Aphandkar** - Independent Director<BR>7. **Heta Shah** - Company Secretary & Compliance Officer<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

Who are the peers of the Genpharmasec?

Genpharmasec's peers include Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, Eforu Entertainm, Constronics, Sharika Enterprises, Safa Systems, and Fortune International. Eforu Entertainm has the highest 1-year return at 58.25%, while Genpharmasec's return is -46.48%.

Peers: The peers of Genpharmasec are Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, Eforu Entertainm, Constronics, Sharika Enterpr., Safa Systems, and Fortune Interntl.<BR><BR>Quality Snapshot: Excellent management risk is observed at Constronics, while Below Average management risk is found at Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, Eforu Entertainm, Genpharmasec, Sharika Enterpr., and Safa Systems. Average growth is noted at Eforu Entertainm and Constronics, while Below Average growth is seen at Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, Genpharmasec, Sharika Enterpr., and Safa Systems. Excellent capital structure is present at Variman Global, while Good capital structure is found at Bombay Cycle, Average at Constronics, and Below Average at Uma Exports, Ganesha Ecoverse, Eforu Entertainm, Genpharmasec, Sharika Enterpr., and Safa Systems.<BR><BR>Return Snapshot: Eforu Entertainm has the highest 1-year return at 58.25%, while Variman Global has the lowest at -69.36%. Genpharmasec's 1-year return of -46.48% is better than Variman Global's but worse than Eforu Entertainm's. Additionally, the six-month return is negative for Variman Global, Uma Exports, Bombay Cycle, Ganesha Ecoverse, Genpharmasec, Constronics, and Safa Systems.

What does Genpharmasec do?

Genpharmasec Ltd, a Micro Cap company in the Trading & Distributors industry, reported net sales of 55 Cr and a net profit of 1 Cr for March 2026. Originally incorporated as Adi Rasayan Limited in 1992, it changed its name in 2018 and has a market cap of INR 62 Cr.

Overview:<BR>Genpharmasec Ltd operates in the Trading & Distributors industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Genpharmasec Ltd was originally incorporated as Adi Rasayan Limited in 1992. The company changed its name to Genpharmasec Limited on November 27, 2018. The latest reported quarterly results show net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 55 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 62 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 143.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.38 <BR>Return on Equity: 0.66% <BR>Price to Book: 0.93 <BR><BR>Contact Details:<BR>Address: Office 104 & 105 1st Flr, Gundecha Indl Kandivali (East) Mumbai Maharashtra : 400101 <BR>Email: genericpharmasec09@gmail.com <BR>Website: http://www.genpharmasec.com

Are Genpharmasec Ltd latest results good or bad?

Genpharmasec Ltd's latest results show strong revenue growth with Q4 FY26 net sales at ₹55.43 crores, a 295.65% increase year-on-year. However, significant profitability concerns arise from a 555.56% decline in net profit and reliance on non-operating income, leading to a cautious investment outlook with a "STRONG SELL" rating.

Genpharmasec Ltd's latest results present a mixed picture. On one hand, the company achieved its highest-ever quarterly revenue in Q4 FY26, with net sales reaching ₹55.43 crores, reflecting an impressive year-on-year growth of 295.65% and a sequential increase of 39.17%. This indicates strong business expansion in the trading and distribution segment.<BR><BR>However, the profitability aspect raises significant concerns. The consolidated net profit for the quarter was ₹1.23 crores, which is a staggering decline of 555.56% year-on-year. This sharp drop highlights the company's fragility in generating sustainable profits, as over half of its profit before tax came from non-operating income, raising questions about the quality and sustainability of its earnings.<BR><BR>While the operating margin improved to 3.61% from a negative margin in the previous year, it remains low and indicates inconsistent operational efficiency. Additionally, the average return on equity (ROE) over the past five years is a mere 1.03%, suggesting poor capital efficiency.<BR><BR>Overall, despite the strong revenue growth, the underlying profitability issues and heavy reliance on non-operating income lead to a negative assessment of the company's financial health. The investment outlook is cautious, with a "STRONG SELL" rating reflecting concerns about long-term earnings quality and competitive positioning.

Should I buy, sell or hold Genpharmasec Ltd?

How has been the historical performance of Genpharmasec?

Genpharmasec has experienced steady revenue growth from 25.52 Cr in Mar'23 to 33.72 Cr in Mar'25, but operating profit has fluctuated, with a recovery in profit after tax from a loss in Mar'24 to 1.23 Cr in Mar'25. The company faces challenges in managing expenses and cash flow despite overall growth.

Answer:<BR>The historical performance of Genpharmasec shows a mixed trend over the past three years, with notable fluctuations in revenue and profit metrics.<BR><BR>Breakdown:<BR>Genpharmasec's net sales have increased from 25.52 Cr in Mar'23 to 30.41 Cr in Mar'24, and further to 33.72 Cr in Mar'25, indicating a steady growth in total operating income. The total expenditure has also risen, from 25.26 Cr in Mar'23 to 30.36 Cr in Mar'24, and 33.66 Cr in Mar'25, reflecting increased costs in purchases and employee expenses. Operating profit, however, has shown variability, with a peak of 0.36 Cr in Mar'23, dropping to 0.05 Cr in Mar'24, and slightly recovering to 0.06 Cr in Mar'25. Profit before tax improved significantly from 0.28 Cr in Mar'23 to 1.88 Cr in Mar'25, while profit after tax showed a recovery from a loss of 0.17 Cr in Mar'24 to a profit of 1.23 Cr in Mar'25. The company's total assets have increased from 19.03 Cr in Mar'23 to 79.43 Cr in Mar'25, with total liabilities also rising from 19.03 Cr to 79.43 Cr in the same period. Cash flow from operating activities improved from -3.00 Cr in Mar'23 to 2.00 Cr in Mar'25, although the net cash outflow was -13.00 Cr in Mar'25, down from a net inflow of 16.00 Cr in Mar'24. Overall, while Genpharmasec has shown growth in sales and profit recovery, it faces challenges in managing expenses and cash flow.

Is Genpharmasec overvalued or undervalued?

As of August 8, 2025, Genpharmasec is considered overvalued with a PE ratio of 45.35 and negative ROCE, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -35.60%.

As of 8 August 2025, Genpharmasec's valuation grade has moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued, with a PE ratio of 45.35, an EV to EBITDA ratio of 111.26, and a PEG ratio of 0.10. These ratios suggest that the stock is trading at a premium compared to its earnings potential, especially when considering its negative ROCE of -0.42% and a low ROE of 1.25%.<BR><BR>In comparison to its peers, Genpharmasec's valuation stands out as particularly high. For instance, Lloyds Enterprises has a PE ratio of 186.85 and MMTC has a PE ratio of 133.83, both categorized as risky, while PTC India, which is very attractive, has a PE ratio of just 8.33. This stark contrast highlights the overvaluation of Genpharmasec within its industry. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -35.60% compared to the Sensex's 2.20%, further reinforcing the notion that Genpharmasec is overvalued.

What is the technical trend for Genpharmasec?

As of May 13, 2025, Genpharmasec's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

As of 13 May 2025, the technical trend for Genpharmasec has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and Bollinger Bands show a bearish trend on both weekly and monthly time frames. The KST is mildly bullish weekly but bearish monthly, and Dow Theory indicates a mildly bullish trend on the weekly chart with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

Who are the top shareholders of the Genpharmasec?

The top shareholders of Genpharmasec are Sneha Sadhwani, the promoter with 16.8%, and public shareholder Yogeshkumar Rasiklal Sanghavi with 7.07%. Individual investors hold a combined 59.94% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Genpharmasec include Sneha Sadhwani, who is the promoter with the highest holding at 16.8%. The highest public shareholder is Yogeshkumar Rasiklal Sanghavi, holding 7.07%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 59.94% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Genpharmasec declared dividend?

No Dividend History Available